Targeting fibrocytes in Duchenne muscular dystrophy

  • Zhou, Lan (CoPI)
  • Zhou, Lan (PI)

Project Details

Description

DESCRIPTION (provided by applicant): Abstract: Muscle fibrosis is a prominent pathological feature of chronic muscle diseases, including muscular dystrophies. It directly leads to muscle dysfunction and clinical muscle weakness. Duchenne muscular dystrophy (DMD) is the most common genetic muscle disease with no cure at this point. Previous studies by our lab and others have demonstrated that ameliorating muscle fibrosis represents a viable therapeutic approach to improve muscular dystrophy phenotype in mdx mice, a mouse model for DMD. Fibrosis is caused by excessive deposition of extracellular matrix (ECM) proteins, which are primarily produced by tissue effector fibroblasts. Extensive research in fibrotic disease models of non-muscle tissues has shown that the circulation-derived fibrocyte is an important cellular mediator of tissue fibrogenesis by producing ECM proteins and profibrotic cytokines as well as differentiating into tissue effector fibroblasts. The chemokine system is essential to the recruitment and fibrogenic functions of fibrocytes. Our preliminary study showed that fibrocytes were also present in a DMD patient muscle biopsy and in mdx diaphragm, the only skeletal muscle in mdx mice that undergoes progressive fibrosis. We further showed that mdx diaphragm fibrocytes expressed chemokine receptors CCR1, CCR2, CCR5, and CXCR4. This study is to address our central hypothesis that fibrocytes play a pathogenic role in skeletal muscle fibrogenesis associated with DMD, the chemokines and chemokine receptors are involved in skeletal muscle recruitment and fibrogenic functions of fibrocytes, and blocking relevant chemokine receptors and their ligands can inhibit fibrocyte recruitment and fibrogenic functions and ameliorate fibrosis in dystrophic muscles. We will address our hypothesis through three Specific Aims. Specific Aim 1 will characterize muscle recruitment and effector properties of mdx diaphragm fibrocytes. Specific Aim 2 will characterize the chemokine receptors and ligands involved in mdx diaphragm fibrocyte recruitment and fibrogenic functions. Specific Aim 3 will test therapeutic interventions to inhibit chemokine receptors and ligands identified in Aim 2 to establish novel therapeutic targets for DMD. Our long-term goal is to utilize the knowledge gained from these studies to develop novel antifibrotic therapies for DMD.
StatusFinished
Effective start/end date1/04/1131/03/17

Funding

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases: $381,375.00
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases: $381,375.00
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases: $362,306.00
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases: $373,748.00
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases: $207,073.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.